OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Parkinson’s disease therapy: what lies ahead?
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 15
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 15
Showing 15 citing articles:
Mild cognitive impairment in Parkinson's disease: current view
K. A. Jellinger
Frontiers in Cognition (2024) Vol. 3
Open Access | Times Cited: 7
K. A. Jellinger
Frontiers in Cognition (2024) Vol. 3
Open Access | Times Cited: 7
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Oxytetracycline and its Non-Antibiotic Derivative DOT Protect Midbrain Dopamine Neurons from Iron-Driven Oxidative Damage
Telma Fernandes, Aurore Tourville, Ismaïla Ciss, et al.
Neurotoxicity Research (2025) Vol. 43, Iss. 2
Closed Access
Telma Fernandes, Aurore Tourville, Ismaïla Ciss, et al.
Neurotoxicity Research (2025) Vol. 43, Iss. 2
Closed Access
Felipe Grünenwald, Tomas Javier Huerta, Denisse Sepúlveda, et al.
Aging Cell (2025)
Open Access
Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
Fengjiao Wang, Guangjie Zhang, Qingfeng Zhai
Frontiers in Neuroscience (2025) Vol. 19
Open Access
Fengjiao Wang, Guangjie Zhang, Qingfeng Zhai
Frontiers in Neuroscience (2025) Vol. 19
Open Access
Cerebral biomimetic nano-drug delivery systems: A frontier strategy for immunotherapy
Hao Tian, Jiaxin Yao, Qi Ba, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 1039-1067
Closed Access | Times Cited: 3
Hao Tian, Jiaxin Yao, Qi Ba, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 1039-1067
Closed Access | Times Cited: 3
The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study
Zhuoqun Wang, Jing Tian, Weixin Dai, et al.
Actas Españolas de Psiquiatría (2024) Vol. 52, Iss. 5, pp. 607-615
Open Access | Times Cited: 2
Zhuoqun Wang, Jing Tian, Weixin Dai, et al.
Actas Españolas de Psiquiatría (2024) Vol. 52, Iss. 5, pp. 607-615
Open Access | Times Cited: 2
Beyond boundaries: Neuroprotective effects of steroids and ecdysteroids in SH‐SY5Y cells ‐ A systematic review
Bizhar Ahmed Tayeb, Isaac Kinyua Njangiru, Renáta Minorics
Neuroprotection/Neuroprotection (Chichester, England. Print) (2024) Vol. 2, Iss. 2, pp. 151-166
Open Access | Times Cited: 1
Bizhar Ahmed Tayeb, Isaac Kinyua Njangiru, Renáta Minorics
Neuroprotection/Neuroprotection (Chichester, England. Print) (2024) Vol. 2, Iss. 2, pp. 151-166
Open Access | Times Cited: 1
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
Giuseppe Pasculli, Pierpaolo Busan, Eric S. Jackson, et al.
Frontiers in Human Neuroscience (2024) Vol. 18
Open Access | Times Cited: 1
Giuseppe Pasculli, Pierpaolo Busan, Eric S. Jackson, et al.
Frontiers in Human Neuroscience (2024) Vol. 18
Open Access | Times Cited: 1
AR71, Histamine H3 Receptor Ligand—In Vitro and In Vivo Evaluation (Anti-Inflammatory Activity, Metabolic Stability, Toxicity, and Analgesic Action)
Anna Stasiak, Ewelina Honkisz-Orzechowska, Z Gajda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8035-8035
Open Access | Times Cited: 1
Anna Stasiak, Ewelina Honkisz-Orzechowska, Z Gajda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8035-8035
Open Access | Times Cited: 1
Novel Therapeutic Horizons: SNCA Targeting in Parkinson’s Disease
Alessio Maria Caramiello, Valentina Pirota
Biomolecules (2024) Vol. 14, Iss. 8, pp. 949-949
Open Access | Times Cited: 1
Alessio Maria Caramiello, Valentina Pirota
Biomolecules (2024) Vol. 14, Iss. 8, pp. 949-949
Open Access | Times Cited: 1
Disease Severity Index in Parkinson’s Disease Based on Self-Organizing Maps
Suellen M. Araújo, Sabrina Beatriz Mendes Nery, Bianca Magalhães, et al.
Applied Sciences (2023) Vol. 13, Iss. 18, pp. 10019-10019
Open Access | Times Cited: 2
Suellen M. Araújo, Sabrina Beatriz Mendes Nery, Bianca Magalhães, et al.
Applied Sciences (2023) Vol. 13, Iss. 18, pp. 10019-10019
Open Access | Times Cited: 2
Small Molecules in Parkinson’s Disease Therapy: From Dopamine Pathways to New Emerging Targets
Hwa‐Young Lee, Ahmed Elkamhawy, Polina Rakhalskaya, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1688-1688
Open Access
Hwa‐Young Lee, Ahmed Elkamhawy, Polina Rakhalskaya, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1688-1688
Open Access
The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson’s disease
Xiaoxue Bai, Jiawei Zhu, Yao Chen, et al.
Future Medicinal Chemistry (2024), pp. 1-16
Closed Access
Xiaoxue Bai, Jiawei Zhu, Yao Chen, et al.
Future Medicinal Chemistry (2024), pp. 1-16
Closed Access
